Stocklytics Platform

Income Statement (CLDX)

itemDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
EBIT-$56.02M-$52.12M-$46.31M-$40.60M-$35.12M
EBITDA-$55.20M-$51.34M-$45.52M-$39.83M-$34.36M
gross Profit$1.17M$3.19M$1.70M-$619.00K$3.37M
NET Income-$47.09M-$42.12M-$35.84M-$32.80M-$43.30M
total Revenue$1.17M$3.19M$2.49M$156.00K$4.13M

Balance Sheet (CLDX)

itemDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
cash Equivalents-----
net Debt-$24.54M-$33.31M-$40.35M-$112.96M-$32.27M
stockholders Equity$747.00M$785.90M$813.65M$838.61M$429.17M
total Assets$792.34M$823.17M$845.58M$868.84M$465.62M
total Debt$3.81M$3.08M$2.38M$2.11M$2.54M
total Liabilities$45.33M$37.27M$31.92M$30.23M$36.45M

Cash Flow (CLDX)

itemDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
financing Cash Flow$386.00K$1.23M$3.71M$436.11M$217.37M
free Cash Flow-$33.23M-$54.71M-$29.60M-$40.98M-$33.19M
investing Cash Flow-----
operating Cash Flow-$32.47M-$55.33M-$29.32M-$40.63M-$32.53M

Celldex Therapeutics (CLDX)

-
add Celldex Therapeutics to watchlist

Keep an eye on Celldex Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level